Deutsche Bank AG Purchases 216,882 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• Deutsche Bank AG has increased its stake in Amicus Therapeutics by 26.4%, owning over 1 million shares worth approximately $8.5 million after additional purchases in Q1.
• Shares of Amicus Therapeutics have seen a 3.9% increase recently, with analysts providing mixed ratings and adjusting price targets ranging from $9.00 to $22.00.
• Institutional investors like Allspring Global Investments and Victory Capital have also significantly boosted their positions in Amicus Therapeutics during the first quarter.

Deutsche Bank AG raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 26.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,038,990 shares of the biopharmaceutical company's stock after acquiring an additional 216,882 shares during the period. Deutsche Bank AG owned approximately 0.34% of Amicus Therapeutics worth $8,478,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics in the 4th quarter valued at $29,000. PNC Financial Services Group Inc. raised its holdings in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Amicus Therapeutics in the 4th quarter valued at $59,000. GAMMA Investing LLC raised its holdings in Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares in the last quarter. Finally, Bryce Point Capital LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at $100,000.

Analysts Set New Price Targets

FOLD has been the subject of several analyst reports. UBS Group lifted their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wall Street Zen raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Finally, The Goldman Sachs Group lowered their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.06 during midday trading on Wednesday, reaching $7.40. 2,458,953 shares of the stock were exchanged, compared to its average volume of 4,500,399. The stock has a market capitalization of $2.28 billion, a PE ratio of -61.66 and a beta of 0.53. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The company has a fifty day moving average price of $6.29 and a 200 day moving average price of $7.23.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.